HK Stock Market Move | LAEKNA-B (02105) morning rise nearly 15% related to exclusive licensing agreement for LAE118 has made new progress, has received Vasque Bio first payment.

LAEKNA-B (02105) rose nearly 15% in the morning session, with a 14.63% increase recorded at the time of publication, trading at 7.13 Hong Kong dollars with a turnover of 9.0682 million Hong Kong dollars. In terms of news, according to an announcement by Laikai Pharmaceuticals, they have made progress in the exclusive licensing agreement for LAE118 (a novel PI3K pan-mutant selective inhibitor) signed with Vasque Bio on June 9th. The group has received an initial payment from Vasque Bio as per the licensing agreement, which includes 10 million US dollars in cash and an equity stake - giving the group the right to receive an equity stake of up to a high double-digit percentage of Vasque Bio's issued common stock without additional consideration, or a cash payment in lieu of such common stock. As per the terms and conditions of the licensing agreement, if Vasque Bio enters into a qualified strategic partnership or acquisition transaction related to the use of LAE118, the group will have the right to receive additional payments, up to 50% of the value of the strategic transaction. LAE118, developed by Laikai Pharmaceuticals, is a novel PI3K pan-mutant selective inhibitor that has been granted investigational new drug (IND) approval by the Food and Drug Administration (FDA) in the United States and the Center for Drug Evaluation (CDE) of the China National Medical Products Administration. As a new therapy for solid tumors with PIK3CA mutations, Laikai Pharmaceuticals is actively advancing this candidate drug into clinical research.